I-Corps at NIH

I-Corps at NIH
Name	I-Corps at NIH
Formation	2014
Type	Entrepreneurship training program
Parent organization	National Institutes of Health
Key people	Matthew Portnoy
Website	https://sbir.nih.gov/icorps

I-Corps at NIH is an entrepreneurial training program administered by the National Institutes of Health designed to accelerate the translation of biomedical discoveries into commercial products and public health solutions. Modeled after the National Science Foundation's I-Corps program, it provides researchers with structured mentorship and a framework to validate the commercial potential of their innovations. The initiative is a key component of the NIH Small Business Innovation Research and Small Business Technology Transfer programs, focusing on reducing the high failure rate of early-stage biotechnology ventures by emphasizing rigorous customer discovery.

Overview

Launched in 2014, I-Corps at NIH operates under the leadership of the NIH Office of Extramural Research and is coordinated by the National Cancer Institute. The program was established to address the unique valley of death challenges in translating fundamental biomedical research into viable products that benefit patients. It leverages the Lean Launchpad methodology, which emphasizes iterative hypothesis testing and direct engagement with the healthcare ecosystem. Participation is typically a prerequisite for teams seeking subsequent Phase II funding through the SBIR and STTR programs at NIH, underscoring its role as a critical gatekeeper for commercial development.

Program Structure and Components

The core of the program is an intensive, eight-week cohort-based course where multidisciplinary teams, composed of a Technical Lead, an Entrepreneurial Lead, and an Industry Mentor, conduct extensive customer discovery interviews. This curriculum is delivered through a combination of virtual instruction, weekly webinars led by experienced instructors from the I-Corps Nodes network, and direct mentorship. Teams are required to complete a minimum of 100 interviews with stakeholders across the biopharmaceutical industry, clinical practice, payer organizations, and patient groups. The program culminates in a final presentation where teams present a refined business model canvas and a definitive go/no-go decision regarding commercial pursuit of their technology.

Eligibility and Application Process

Eligibility is primarily extended to current or recent awardees of the NIH SBIR or STTR programs, specifically those holding a Phase I contract. Applications are submitted through the official NIH Submission Center and are reviewed by a panel of experts in venture capital, biotech entrepreneurship, and technology transfer. Selection criteria heavily weigh the potential for significant public health impact, the novelty of the underlying science, and the commitment of the proposed team members. Notable participating institutes include the National Institute of Allergy and Infectious Diseases, the National Heart, Lung, and Blood Institute, and the National Institute of Neurological Disorders and Stroke.

Impact and Outcomes

Since its inception, I-Corps at NIH has trained hundreds of teams, leading to the formation of numerous startup companies and the successful licensing of technologies to established firms like Johnson & Johnson and Roche. The program has been instrumental in de-risking early-stage investments, with alumni reporting significantly increased success rates in securing follow-on funding from sources such as the Biomedical Advanced Research and Development Authority, venture capital firms, and angel investors. Quantitative assessments show that participating teams pivot their commercial strategy in over 70% of cases based on evidence gathered during customer discovery, demonstrating the program's effectiveness in aligning research with market needs.

Relationship to NSF I-Corps

While I-Corps at NIH is an adaptation of the foundational NSF I-Corps program created by Steve Blank, it is tailored specifically to the complexities of the life sciences and regulatory pathways governed by the Food and Drug Administration. The curriculum places greater emphasis on navigating clinical trials, reimbursement models from Centers for Medicare & Medicaid Services, and engagement with key opinion leaders in medicine. Both programs share instructional resources and best practices through the national I-Corps Network, but NIH cohorts are exclusively focused on health-related technologies, unlike the broader engineering and physical science scope of the NSF.

Notable Projects and Success Stories

Notable alumni projects include diagnostic platforms for early detection of sepsis, novel gene therapy vectors for rare diseases, and digital health tools for managing type 2 diabetes. One success story is Kinnos Inc., a company that developed a colorizing additive for disinfectants, which emerged from an I-Corps at NIH cohort and later received support from the Bill & Melinda Gates Foundation. Another is Vascular Simulations, which used the program to validate the market for its patient-specific surgical training models, leading to partnerships with major medical device companies and adoption at institutions like the Mayo Clinic.

Category:National Institutes of Health Category:Entrepreneurship programs Category:Technology transfer